Get started
Author

Jacob Lund

Observed names: J Lund, J. Lund
ORCID: 0000-0001-8627-7382
Observed ORCID: 0000-0001-8627-7382
OpenAlex ID: A5016165428
Mutations in Calmodulin Cause Ventricular Tachycardia and Sudden Cardiac Death
2012 · Mette Nyegaard, Michael T. Overgaard, et al. · The American Journal of Human Genetics · 406
PDF
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
2021 · Henrik Østergaard, Jacob Lund, et al. · Blood · 94
PDF
ADAMDEC1 Is a Metzincin Metalloprotease with Dampened Proteolytic Activity
2013 · Jacob Lund, Ole H. Olsen, et al. · Journal of Biological Chemistry · 31
Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo
2019 · Stine L Kjellev, Henrik Østergaard, et al. · Blood · 22
Heparin-binding mechanism of the IGF2/IGF-binding protein 2 complex
2014 · Jacob Lund, Mads T Søndergaard, et al. · Journal of Molecular Endocrinology · 21
PDF
In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays
2023 · Jacob Lund, Kasper Jensen, et al. · Journal of Thrombosis and Haemostasis · 15
Evidence for Restricted Reactivity of ADAMDEC1 with Protein Substrates and Endogenous Inhibitors
2015 · Jacob Lund, Linda Troeberg, et al. · Journal of Biological Chemistry · 11
Gene editing in hematopoietic stem cells by co-delivery of Cas9/sgRNA ribonucleoprotein and templates for homology-directed repair in ‘all-in-one’ lentivirus-derived nanoparticles
2025 · Sofie Andersen, Jonas Holst Wolff, et al. · Nucleic Acids Research · 7
PDF
Monoclonal antibodies targeting the disintegrin-like domain of ADAMDEC1 modulates the proteolytic activity and enables quantification of ADAMDEC1 protein in human plasma
2017 · Jacob Lund, Anne Mette Elimar Bitsch, et al. · mAbs · 7
PDF
Data transmission by frequency modulation in an automated gas chromatographic system
1978 · E. Bechgaard, J.A. Christensen, et al. · Analytica Chimica Acta · 7
In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure
2025 · Hamdi Rezigue, Laurie Josset, et al. · Thrombosis Research · 6
A systematic approach for evaluating the role of surface-exposed loops in trypsin-like serine proteases applied to the 170 loop in coagulation factor VIIa
2022 · Anders B. Sorensen, Per Greisen, et al. · Scientific Reports · 6
PDF
Site‐specific functional roles of the Factor X activation peptide in the intrinsic tenase‐mediated Factor X activation
2022 · Amalie Carnbring Bonde, Sofie Rosenørn Hansen, et al. · FEBS Letters · 6
PDF
The Distribution of 2‐Amino‐4‐phenylsulphonylbenzenesulphonamide (NSD 3004) in Blood and its Binding to Blood Components
1971 · J. Lund, J. Buus Lassen, et al. · Acta Pharmacologica et Toxicologica · 4
Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays
2026 · Jacob Lund, Mirella Ezban, et al. · Research and Practice in Thrombosis and Haemostasis · 3
PDF
The functional role of the autolysis loop in the regulation of factor X upon hemostatic response
2021 · Amalie Carnbring Bonde, Jacob Lund, et al. · Journal of Thrombosis and Haemostasis · 3
Pharmacological and Biochemical Studies on 2‐Amino‐4‐phenylsulphonylbenzenesulphonamide (NSD 3004): A New Sulphonamide with Anticonvulsant and Carbonic Anhydrase Inhibitory Properties
1971 · J. Buus Lassen, J. A. Christensen, et al. · Acta Pharmacologica et Toxicologica · 3
Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V‐stabilizing fab
2017 · D. F. Brophy, E. J. Martin, et al. · Haemophilia · 2
Mechanism of action and impact on thrombin generation of denecimig (Mim8), emicizumab, and zemocimig (NXT007): comparative analysis using sequence-identical analogs
2026 · Jacob Lund, Thomas Egebjerg, et al. · Research and Practice in Thrombosis and Haemostasis · 1
Comparative ex vivo analysis of Mim8 in thrombin generation assays triggered by activated factor XI or tissue factor
2025 · Wan Hui Ong Clausen, Ties Latendorf, et al. · Research and Practice in Thrombosis and Haemostasis · 1
Development of Inno8, an orally administered factor VIIIa-mimetic antibody fragment for treatment of hemophilia A
2026 · Jacob Lund, Jais Rose Bjelke, et al. · Blood
PDF
PB3413 Denecimig (Mim8) enhances in vitro thrombin generation in von Willebrand disease type 3 plasma
2026 · Jacob Lund, Marianne Kjalke · Research and Practice in Thrombosis and Haemostasis
PB2071 Thrombin generation of hemophilia B-causing factor IX variants with non-factor therapies
2026 · Kyumin Lee, Sebastian Leyes Porello, et al. · Research and Practice in Thrombosis and Haemostasis
PB2093 Effects of denecimig (Mim8) and tranexamic acid in an in vitro clot lysis assay
2026 · Marianne Kjalke, Jacob Lund · Research and Practice in Thrombosis and Haemostasis
PB2069 Denecimig (Mim8) restores thrombin generation into the normal range in people with haemophilia A: Post hoc analysis of the phase 3 FRONTIER2 and FRONTIER5 studies
2026 · Guy Young, Flora Peyvandi, et al. · Research and Practice in Thrombosis and Haemostasis
Works count: 31
Citation count: 656
H-index: 7
I10-index: 7
Year
Topic
Type